Clinical trials: Vision Disorder
Hyperopia
Hyperopia Correction Using the NTK Optimal Keratoplasty (Opti-K) System
The purpose of this U.S. Clinical Trial on treatment of sighted eyes is to investigate the safety and effectiveness of optimal keratoplasty (Opti-K™) treatments for hyperopia correction using the NTK Enterprises (NTK) Opti-K…
- Trial name
- NCT01028937
- Testing
- Optimal Keratoplasty
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- NTK Enterprises, Inc.
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pharyngitis, Tonsillitis
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
This Post-Authorization Safety Study (PASS) is intended to fulfill a regulatory post-marketing requirement to provide data regarding visual abilities in children taking azithromycin (immediate-release formulation) for acute…
- Trial name
- NCT01919996
- Testing
- Azithromycin
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.
- Trial name
- NCT01637246
- Testing
- Any Fixed Combination Therapy
- Where
- Spain
- Volunteers
- 4,385 people
- Sponsor
- Allergan
Open-Angle Glaucoma, Ocular Hypertension
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
The purpose of this study was to describe the ocular discomfort immediately upon instillation of Brinzolamide 1%/Brimonidine 0.2% Tartrate Ophthalmic Suspension, Brinzolamide 1% Ophthalmic Suspension, and Brimonidine Tartrate…
- Trial name
- NCT01426867
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 103 people
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Open-angle, Ocular Hypertension
A Long-term Safety Study of Once-daily Travatan
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051168
- Testing
- Travatan
- Where
- United States
- Volunteers
- 502 people
- Sponsor
- Alcon Research
Inflammation, Pain
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT01298752
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Bausch & Lomb Incorporated
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy.
- Trial name
- NCT00693485
- Testing
- 400 ug Brimonidine Implant, 200 ug Brimonidine Implant
- Where
- 2 sites in United States, Israel
- Volunteers
- 70 people
- Sponsor
- Allergan
Cataract
Evaluation of 3 Intraocular Lenses Following Lens Extraction
The objective of this study is to evaluate the efficacy and subject satisfaction with three different FDA approved lenses for adults over 40 years of age who desire a reduction in spectacle dependence.
- Trial name
- NCT01122576
- Testing
- Crystalens AO, ReSTOR, Tecnis Multifocal IOL
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Bausch & Lomb Incorporated
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
- Trial name
- NCT00539526
- Testing
- Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure
The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02003391
- Testing
- Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
- Volunteers
- 157 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.
- Trial name
- NCT01489670
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Switzerland
- Volunteers
- 387 people
- Sponsor
- Allergan
Diabetes Mellitus, Macular Edema
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular…
- Trial name
- VIVID-DME (NCT01331681)
- Testing
- VEGF Trap-Eye (BAY86-5321), Macular Laser Photocoagulation (Control)
- Where
- 73 sites in Australia, Austria and 9 more
- Volunteers
- 406 people
- Sponsor
- Bayer
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Achromatopsia
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
This is a longer-term follow-up study of patients with achromatopsia associated with defects in CNGA3 who participated in a clinical trial in which they received AAV-CNGA3 retinal gene therapy, or of patients with achromatopsia…
- Trial name
- NCT03278873
- Testing
- Prior exposure to AAV-CNGA3 or AAV-CNGB3
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- MeiraGTx UK II Ltd
Open Angle Glaucoma
Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
To compare the safety and effectiveness of oculusgen (ologen) collagen matrix implantation and Mitomycin-C(MMC) in glaucoma surgery.
- Trial name
- NCT00538590
- Testing
- Collagen Matrix in Glaucoma Filtering Surgery, Mitomycin-C(MMC) and glaucoma filtering surgery
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Pro Top & Mediking Company Limited
Glaucoma, Open Angle Glaucoma
Long-term Safety and Performance of the ARGOS-SC Suprachoroidal Pressure Sensor System in Patients With Glaucoma Underwent Non-penetrating Glaucoma Surgery
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-SC system.
- Trial name
- NCT04773106
- Testing
- ARGOS-SC suprachoroidal pressure sensor
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 22 people
- Sponsor
- Implandata Ophthalmic Products GmbH